BJ Bormann

Independent, Non-executive Board Member at Xeris Pharmaceuticals

BJ Bormann is a professional with almost 30 years of experience in academic and pharmaceutical science and biotechnology and pharmaceutical business development. Her current role is serving as the Vice President of Translational Science and Network Alliances for the Jackson Laboratory. In this role, BJ is working to bring the innovations from the Jackson Laboratory faculty closer to patients by generating a series of collaborative relationships with industrial partners. BJ’s previous work in the biotechnology area includes leading Pivot Pharmaceuticals as the CEO (OTC: PVOTF); the CEO of Supportive Therapeutics, LLC, a company that is developing a drug for the treatment of oral mucositis, a severe side effect to chemoradiation treatment in oncology patients. BJ has previously been the CEO of Harbour Antibodies based in the Netherlands, licensing transgenic mice that make human antibodies, and the Chief Business Advisor for NanoMedical Systems, Inc. of Austin, Texas that licenses a unique implantable drug delivery device. Prior to these engagements, BJ was Senior Vice President responsible for worldwide alliances, licensing, and business development at Boehringer Ingelheim Pharmaceuticals, Inc. from 2007 to 2013. From 1996 to 2007, she served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and the worldwide Head of Strategic Alliances. BJ currently serves on the board of directors of various companies, including Supportive Therapeutics, LLC, the Institute for Pediatric Innovation, and Bioline RX (Nasdaq: BLRX).

Dr. Bormann received her Ph.D. in Biomedical Sciences from the University of Connecticut Health Center and her BS from Fairfield University in Biology. Dr. Bormann completed postdoctoral training at the Yale School of Medicine in the Department of Pathology.

Timeline

  • Independent, Non-executive Board Member

    Current role